Cinolazepam

Cinolazepam
Clinical data
Trade names	Gerodorm 40mg
AHFS/Drugs.com	cinolazepam
Dependence; liability	High
Addiction; liability	Medium
Routes of; administration	Oral
ATC code	N05CD13 (WHO) ;
Legal status
Legal status	US: Unscheduled; EU: Prescription drug;
Pharmacokinetic data
Bioavailability	90–100%
Metabolism	Hepatic
Onset of action	30 minutes to 1 hour
Elimination half-life	9 hours
Duration of action	9 hours
Excretion	Renal
Identifiers
	IUPAC name (RS)-3-[9-Chloro-6-(2-fluorophenyl)-4-hydroxy-3-oxo-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-2-yl]propanenitrile;
CAS Number	75696-02-5 ;
PubChem CID	3033621;
DrugBank	DB01594 ;
ChemSpider	2298251 ;
UNII	68P0556B0U;
KEGG	D07328 ;
ChEBI	CHEBI:59514 ;
ChEMBL	ChEMBL2104926 ;
CompTox Dashboard (EPA)	DTXSID30868372 ;
Chemical and physical data
Formula	C18H13ClFN3O2
Molar mass	357.77 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES FC1=CC=CC=C1C2=NC(C(N(CCC#N)C3=C2C=C(C=C3)Cl)=O)O;
	InChI InChI=1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2 ; Key:XAXMYHMKTCNRRZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Cinolazepam^[1] (marketed under the brand name Gerodorm)^[2] is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Due to its strong sedative properties, it is primarily used as a hypnotic.

It was patented in 1978 and came into medical use in 1992.^[3] Cinolazepam is not approved for sale in the United States or Canada.

^ US Patent 4388313 Novel 3-hydroxy-1,4-benzodiazepine-2-ones and process for the preparation thereof
^ Lannacher Romania (1999). "Gerodorm". Produse Gerot inregistrate in Romania (in Romanian). Archived from the original on 11 October 2006. Retrieved 17 August 2006.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 530. ISBN 9783527607495.